

## APA DSM-V Task Force Member Disclosure Report

Name : Charles P O'Brien MD PhD  
Job Title : Professor and Director, Center for Study of Addiction  
Address : 3900 Chestnut St  
Philadelphia PA 19104-3120  
Role : **Member**  
Date : **5/2/2011**

### Task Force:

Task Force on DSM-V

### Biographical Sketch

#### Biographical Sketch:

Charles P. O'Brien, a native of New Orleans, earned M.D. and Ph.D. degrees from Tulane University. He received residency training at Harvard, Tulane, University of London, and University of Pennsylvania in internal medicine, neurology and psychiatry. As Chief of Psychiatry at the Philadelphia VA Medical Center, he was responsible for over 9,000 psychiatric patients. Despite this large clinical responsibility, he was able to establish and direct a clinical research program that has had a major impact on the treatment of addictive disorders. His research group has been responsible for numerous discoveries described in over 450 publications that have elucidated basic information on the nature of addiction and improved the results of treatment for addictive disorders. His work involves discovery of CNS changes involved in relapse, new medications, behavioral treatments and instruments for measuring the severity of addictive disorders. Many of these discoveries are now utilized in common practice for the treatment of addictive disorders throughout the world.

O'Brien's recent work has focused on a genetic subtype of alcoholism. A functional allele of the  $\mu$  opiate receptor predicts response to alcohol and carries an increased risk of both alcoholism and opiate addiction. O'Brien's group reported a significant improvement in outcome among alcoholics when carriers of this allele are randomized to treatment with the opiate receptor antagonist naltrexone. This finding was replicated recently by another group. His group also recently discovered a medication that is effective against cocaine addiction and there is already a preliminary report of a replication. His work is on the cutting edge of new treatments for addictive disorders.

O'Brien was elected to the Institute of Medicine of the National Academy of Sciences in 1991 and he has received numerous research awards as well as an honorary doctorate from the University of Bordeaux in 1994 and the Nathan B. Eddy award for research on addiction from the College on Problems of Drug Dependence in 2003. He has been an adviser on drug policy to local and national governments since the 1970s and has chaired or served as member of numerous IOM committees dealing with the science and policy matters of abused drugs and is currently chair of the substance use disorders committee for DSM-V. O'Brien is past president of the American College of Neuropsychopharmacology and the Association for Research in Nervous and Mental Disease. Currently he is Kenneth Appel Professor and Vice-Chair of Psychiatry at the University of Pennsylvania, Vice Director of the Institute of Neurological Sciences and Director of the Center for Studies of Addiction. At the VA medical center, he continues as Director of Research for the Mental Illness Research, Education and Clinical Center.

The table below represents the disclosure for Dr.Charles P O'Brien MD PhD of significant interests and affiliations for the three years prior to the DSM Task Force or a DSM Work Group member nomination and the period prior to public announcement of his/her appointment. The table also represents the reported disclosures of significant interests and affiliations for the past full calendar year and the current year to date for Dr.Charles P O'Brien MD PhD.

Dr. Charles P O'Brien MD PhD has agreed that, from the time of approval through the publication of DSM-V, projected in 2013, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Relationship</b>	<b>Key(s)</b>
Alkermes/Cephalon	2005 - 2008	Self	Consultation
Forest Pharmaceuticals	2005 - 2006	Self	Consultation
Eli Lilly and Company	2006 - 2006	Self	Consultation
Forest Laboratories, Inc	2005 - 2006	Self	Honoraria
US World Meds	2003 - 2007	Self	Consultation
Hythiam	2007 - 2007	Self	Consultation
McNeil Consumer & Specialty Pharmaceutical	2005 - 2005	Self	Consultation
Pfizer Inc.	2003 - 2003	Self	Grant
Sanofi-Aventis	2003 - 2003	Self	Consultation
Sanofi-Aventis	2003 - 2003	Self	Grant
Johnson & Johnson	2005 - 2005	Self	Consultation
GlaxoSmithKline, Inc.	2005 - 2006	Self	Consultation
Merck & Co.	2008 - 2008	Self	Consultation
Purdue Frederick Company	2008 - 2008	Self	Consultation
Best Practices	2005 - 2005	Self	Consultation
Pfizer Inc.	2008 - 2008	Self	Consultation
Schering-Plough	2005 - 2005	Self	Honoraria
Abbott Laboratories	2009 - 2009		Consultation
Embera	2009 - 2009		Consultation
Reckitt	2010 - 2010	Self	Consultation
Gilead	2010 - 2010	Self	Consultation
Alkermes	2010 - 2011	Self	Consultation

The table below represents the reported disclosures of uncompensated leadership positions with Non-Profit or Advocacy Organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V for the three years prior to appointment and the current year to date for Charles P O'Brien MD PhD.

<b>Non-Profit or Advocacy Organization</b>	<b>Year(s)</b>	<b>Relationship</b>	<b>Role</b>
Treatment Research Institute	1992 - Present	Self	Board of Directors
Depression and Bipolar Support Association	2000 - Present	Self	Scientific Advisory Board
Neuroleptic Malignant Syndrome Information Service	1997 - Present	Self	Scientific Advisory Board
American College of Neuropsychopharmacology	1976 - Present	Self	President, Council Ethics Committee
American Foundation for Suicide Prevention	2002 - Present	Self	Scientific Advisory Board